Johnson & Johnson JNJ

271.22 0.54 0.20% as of 25 Sep
Market cap
$652.8B
P/E
31.4×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

Johnson & Johnson (JNJ) Gross margin

Johnson & Johnson's gross margin over the twelve months to 30 June 2026 was 67.9%, up 0.0 percentage points from fiscal 2025 (67.9%). Over the past ten years it has ranged from 65.6% (fiscal 2020) to 70.3% (fiscal 2021); the current reading is higher than 45% of that period. That is below the Drug Manufacturers General industry median of 72.8% and above the Healthcare sector median of 53.7%.

Gross margin, annual

Annual

Period Gross margin Change (points)
FY2025 67.9% (1.19)
FY2024 69.1% 0.25
FY2023 68.8% (0.43)
FY2022 69.3% (1.03)
FY2021 70.3% 4.70
FY2020 65.6% (0.84)
FY2019 66.4% (0.37)
FY2018 66.8% 0.07
FY2017 66.7% (2.97)
FY2016 69.7% 0.42

Quarterly

Period Gross margin Change (points)
Jun 2026 68.2% 1.88
Mar 2026 66.3% (1.25)
Dec 2025 67.6% (2.00)
Sep 2025 69.6% 1.69
42 more quarters

Against its own ten years

Low 65.6% High 70.3%
Ten-year median 68.8%
Current reading's percentile 45

Gross margin against peers

Company Gross margin
LLY Eli Lilly and Company compare 83.4%
AZN AstraZeneca PLC compare 81.9%
GILD Gilead Sciences, Inc. compare 79.6%
NVS Novartis AG compare 74.7%
PFE Pfizer Inc. compare 73.2%
MRK Merck & Co., Inc. compare 73.0%
ABBV AbbVie Inc. compare 71.5%
AMGN Amgen Inc. compare 69.5%
JNJ Johnson & Johnson 67.9%
Drug Manufacturers General industry median 72.8%
Healthcare sector median 53.7%
Market median 46.3%

What Gross margin is

Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.

Gross Profit ÷ Revenue

The full definition of Gross margin →

More on JNJ